Illumina’s New Sequencers


The genetics world was rocked by a surprise announcement from its most prominent company: Illumina is secretly owned by Apple. At least, that would explain the company’s obvious joy at making their previous products look obsolete, and the way their competitors have to constantly protest that, yes, Illumina’s latest gadget is obviously very cool, but wouldn’t you like to compare prices and specifications? Get the facts here on what you should know before you shop for your next gadget. One thing I think is of utmost importance. This is to check the compatibility of the gadget with other gadgets. If the gadget is compatible with all the devices that you use then it makes it easy for you to transfer data from one device to another.(This theory…
Read More
Actelion obtains option to acquire privately-held …
Late-stage Phase III compound in Amyotrophic Lateral Sclerosis to report data in late 2011 – Novel therapeutic approach to be further explored in drug discovery collaboration ALLSCHWIL, SWITZERLAND and MARSEILLE, FRANCE – 20 July 2010 – Actelion Ltd (SIX: ATLN) and privately-held Trophos SA announced today that they have entered into a binding agreement whereby Actelion has, for EUR 10 million, obtained an exclusive…
Read More
Sanofi-aventis’ purchase aligned with techno…
Sanofi-aventis’ acquisition of the pharmaceutical development company that began as Selectide is “coincident with the technology, essentially, coming of age,” according to Tucson Research Center scientific director Ken Wertman. “It is inextricably tied to this sense we have reached the objective;” namely, to use technology to effectively develop and analyze compounds for further…
Read More
2009: The Year That Was For Pfizer
(RTTNews) – True to expectations, Jeffrey Kindler, the CEO of Pfizer Inc. (PFE | Quote | Chart | News | PowerRating), scripted a new playbook for the drug giant in 2009, accelerating the process of transformation by clinching the largest pharmaceutical deal in nearly a decade. The acquisition of Wyeth for $68 billion earlier this year represents a major move by Pfizer to plug the impending holes in its…
Read More
Commonwealth Biotechnologies, Inc. Acquisition of …
Shareholders approve sale of the Richmond, Virginia assets as required under the GL Biochem Asset Purchase Agreement RICHMOND, Va.–(Business Wire)– Commonwealth Biotechnologies, Inc. (“CBI”) (NASDAQ Capital Market: CBTE) has recently announced a definitive share purchase agreement to acquire Shanghai-based GL Biochem and associated businesses (the “GL Group”), the largest global supplier of…
Read More
Eurogentec Announces Agreement to Acquire AnaSpec…
Liège, Belgium—October 23, 2009. Eurogentec S.A. (“Eurogentec”) announces today a final agreement for the acquisition of AnaSpec Inc (“AnaSpec” or the “Company”), a privately held proteomics company based in Fremont, California. Founded in 1993, AnaSpec is a leading provider of integrated proteomics solutions for life science research and diagnostics with expertise in peptides…

Share:

You might also like …